Loading, Please Wait...
MUNICH, GERMANY--(Marketwired - Mar 21, 2016) - Autonomic Technologies® is a proud supporter of the first Cluster Headache Day to raise awareness of this debilitating disease. March 21, the date of the spring equinox, has been declared Cluster Headache Day by The European Headache Federation (EHF) and European Headache Alliance (EHA).
Cluster headache affects up to 4 in 1,000 people. Despite being relatively unknown, it causes pain of such intensity and frequency that it is referred to as suicide headache. "More than 600,000 people in Europe live with cluster headache, with less than 50% seeing a headache specialist or neurologist and more than a third of sufferers miss work at a cost of 7 billion euro per year," said Prof. Dimos Mitsikostas, President of EHF. Prof. Mitsikostas also explained that the 21st of March, had been selected as Cluster Headache Day because of the common increase in cluster attacks beginning around the time of the spring equinox.
ATI is committed to improving the lives of cluster headache patients. With ATI's unique Pulsante® Microstimulator system, patients across Europe suffering from cluster headache can now get access to a minimally-invasive solution that is clinically proven and effective (http://www.ati-spg.com/europe/en/product-brochure/pulsante-brochure/). "Results from our clinical studies in Europe1 showed that 90% of patients treated with Pulsante would recommend the therapy to someone else after 18 months of use," said Karl Schweitzer President of International at Autonomic Technologies.
About Autonomic Technologies
Autonomic Technologies, Inc. (ATI®) is a medical device company headquartered in the San Francisco Bay Area with offices in Germany and Switzerland, focused on the development and commercialization of innovative therapies for the treatment of autonomic disorders, particularly severe headache. The company's initial product, the Pulsante® Microstimulator, is CE marked in Europe for the treatment of cluster headache. The device (also known as Autonomic Technologies, Inc. (ATI®)) Neurostimulation System) is under an IDE study in the US for the treatment of chronic cluster headache. For more information, please visit: www.pulsante.eu or www.ati-spg.com.
1. Lainez, J. A. May, C. Gaul, J. Schoenen, A. Goodman, A. Caparso and R. Jensen Effectiveness of Sphenopalatine Ganglion (SPG) Stimulation for Cluster Headache: 2 year Long term Follow Up Results from the Pathway CH-1 Study: 17th International Headache Congress, Valencia, Spain. May 2015
Senior Director of Marketing